Processa Pharmaceuticals (PCSA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Processa Pharmaceuticals (PCSA) is Moderate Underperform.

The composite score behind that read is -0.33, weighing +0.00 of bullish evidence against -0.52 bearish.

Processa Pharmaceuticals last closed at $1.52, +12.59% on the session.

Against the IVW growth benchmark the position is +11.79% over the forecast window.

The read is built from 15 underlying insights — 0 bullish and 15 bearish.

Agreement across those insights is 100%.

20 graded predictions for PCSA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Processa Pharmaceuticals in the 3rd percentile on return on equity, where 100 is best.

Processa Pharmaceuticals is classified under Health Care / Pharmaceuticals, with a market capitalisation of $3.77M.

StockMap tracks Processa Pharmaceuticals as the 142nd largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Processa Pharmaceuticals ranks 135th of 151 in the group, against a group median of -0.08.